Amgen has announced that its ongoing cardiovascular drug development collaboration with Servier is to be taken to the next stage.
Servier has chosen to exercise its option to commercialise the drug omecamtiv mecarbil in chronic heart failure in Europe, as well in as the Commonwealth of Independent States, with these terms having now been added to the collaboration.
“Amgen and Servier are advancing their ongoing cardiovascular collaboration, focused on the heart failure therapy omecamtiv mecarbil.“
The companies also announced plans to move the omecamtiv mecarbil phase III development programme forward in collaboration with Cytokinetics. Servier will make a $10 million (7.54 million pounds) payment to Amgen, as well as future milestone fees and royalties.
This decision was based on positive findings from COSMIC-HF, a phase II trial showing the drug was associated with significant improvements in cardiac function.
Dr Sean Harper, executive vice-president of research and development at Amgen, said: "We are very pleased to strengthen our collaboration with Servier and for the continued advancement of the novel cardiac myosin activator omecamtiv mecarbil."
The drug is part of a class of therapies called novel cardiac myosin activators and is being developed in a joint effort between Amgen, Servier and Cytokinetics.
With? ?over? ?20? ?years? ?of? ?experience? ?within? ?the? ?pharmaceutical? ?market,? ?we? ?at? ?Zenopa? ?have? ?the knowledge,? ?skills? ?and? ?expertise? ?to? ?help? ?find? ?the? ?right? ?job? ?for? ?you.? ?To? ?find? ?out? ?more? ?about? ?the current? ?pharmaceutical? ?roles? ?we? ?have? ?available,? ?you? ?can? ?search? ?for? ?the? ?latest? ?job? ?roles, register? ?your? ?details,? ?or? ?contact? ?the? ?team? ?today.See all the latest jobs in Pharmaceutical